Skip to content

A Digital Smoking Cessation Intervention for Helping American Indians and Alaska Natives Quit Smoking, IndigeQuit Trial

Digital Smoking Cessation Intervention for Nationally-Recruited American Indians and Alaska Natives: A Full-Scale Randomized Controlled Trial (IndigeQuit)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06145763
Enrollment
776
Registered
2023-11-24
Start date
2025-07-03
Completion date
2028-11-30
Last updated
2026-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cigarette Smoking-Related Carcinoma

Brief summary

This clinical trial compares a new smoking cessation smartphone application (app) (IndigeQuit) to an existing smarphone app (National Cancer Institute \[NCI\] QuitGuide) for helping American Indians and Alaska Natives (AI/ANs) quit smoking. Compared to other racial/ethnic groups, AIANs have 6 times higher rates of developing smoking-related cancers, including lung cancer. Commercial cigarette smoking accounts for half of all deaths among AIANs nationwide. AIANs' often lack of access to smoking cessation interventions, which may be due to inequities in the healthcare system, lack of health insurance, living in rural areas, systemic racism, and historical trauma. There is also a lack of effective smoking cessation interventions for AIANs. Smartphone apps have the potential to deliver a low-cost smoking cessation intervention with wide reach to AIANs. Apps require no in-person delivery and no provider training, do not require integration into complex hospital systems, can be freely accessed on an app store, and are available at any time and any place. IndigeQuit is a behavioral intervention designed to help adults stop smoking by teaching skills for coping with smoking urges, staying motivated, and preventing relapse. The IndigeQuit app intervention may be more effective than the currently available NCI QuitGuide app at helping AIANs quit smoking.

Detailed description

OUTLINE: Participants are randomized to 1 of 2 arms. ARM I: Participants use the IndigeQuit app, which includes setting up a personalized quit plan, participating in eight levels of the content, receiving on-demand help in coping with smoking urges, and tracking their daily smoking behaviors for at least 45 days on study. ARM II: Participants use the NCI QuitGuide app for at least 45 days on study. After completion of study intervention, patients are followed up at 3, 6, and 12-months.

Interventions

PROCEDUREBiospecimen Collection

Ancillary studies

BEHAVIORALSmoking Cessation Intervention

Use IndigeQuit smartphone app

OTHERSurvey Administration

Ancillary studies

Sponsors

Fred Hutchinson Cancer Center
Lead SponsorOTHER
National Cancer Institute (NCI)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

Random assignments will be concealed from participants and research staff throughout the trial.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Self-identify as American Indian or Alaska Native, either alone or in combination with other races * Age 18 and older * Has smoked daily for the past year * Interest in quitting smoking within the next 30 days * Willing to be randomly assigned to either app * Have daily access to their own Android or iPhone * Able to download a smartphone app * Be willing and able to read English * Not currently or within past 30 days using other smoking cessation behavioral interventions or smoking cessation pharmacotherapies * Have never participated in our prior research * Have no other household or family member participating * Being willing to complete the 3, 6, and 12-month follow-up assessments * Providing email, phone number(s), and mailing address * Living off United States (US) AI/AN tribal reservations or living on five Northern Plains tribal reservations from whom we would obtain approvals to recruit

Exclusion criteria

* Currently (i.e., within past 30 days) using other smoking cessation behavioral interventions * Has participated in our prior research trials * Has used the National Cancer Institute's (NCI's) QuitGuide app * Not willing to complete a follow-up survey at 3, 6, and 12 months post-randomization * Not providing email, phone number(s), and mailing address

Design outcomes

Primary

MeasureTime frameDescription
30-day point prevalence abstinence (PPA)At 12 months post randomizationWill be assessed based on self-report with biochemical verification of salivary cotinine. For each comparison of treatment arms on cessation outcomes, will use a logistic regression model.

Secondary

MeasureTime frameDescription
30-day PPAAt 3- and 6-months post randomizationWill be assessed based on self-report with biochemical verification of salivary cotinine. For each comparison of treatment arms on cessation outcomes, will use a logistic regression model.
Self-reported 24-hour PPAAt the 3, 6, and 12-month follow-upsA secondary definition of cessation will include self-reported abstinence from cigarettes and all other commercial nicotine-containing tobacco products (i.e., e-cigarettes or vaping, chewing tobacco, snus, hookahs, cigars, cigarillos, tobacco pipes, kreteks). Will be assessed based on self-report with biochemical verification of salivary cotinine. For each comparison of treatment arms on cessation outcomes, will use a logistic regression model.
Self-reported 7-day PPAAt the 3, 6, and 12-month follow-upsA secondary definition of cessation will include self-reported abstinence from cigarettes and all other commercial nicotine-containing tobacco products (i.e., e-cigarettes or vaping, chewing tobacco, snus, hookahs, cigars, cigarillos, tobacco pipes, kreteks). Will be assessed based on self-report with biochemical verification of salivary cotinine. For each comparison of treatment arms on cessation outcomes, will use a logistic regression model.

Countries

United States

Contacts

CONTACTBrie Sullivan
bsulliva@fredhutch.org206-667-5238
PRINCIPAL_INVESTIGATORJonathan B. Bricker

Fred Hutch/University of Washington Cancer Consortium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 4, 2026